Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Compugen Ltd.
  6. News
  7. Summary
    CGEN   IL0010852080

COMPUGEN LTD.

(CGEN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Compugen: Q3 Earnings Snapshot

11/12/2021 | 08:02am EST

HOLON, Israel (AP) _ Compugen Ltd. (CGEN) on Friday reported a loss of $6.2 million in its third quarter.

The Holon, Israel-based company said it had a loss of 7 cents per share.

The results beat Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for a loss of 13 cents per share.

The drug developer posted revenue of $6 million in the period.

Compugen shares have fallen 41% since the beginning of the year. The stock has declined 45% in the last 12 months.

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on CGEN at https://www.zacks.com/ap/CGEN

Copyright by Automated Insights, Inc. All rights reserved., source Associated Press News

All news about COMPUGEN LTD.
01/18Compugen Awarded US Patent for Method of Use of Cancer Drug Candidate
MT
01/18Compugen Expands COM701 Intellectual Property Portfolio with New U.S. Patent Covering T..
PR
01/18Compugen Expands COM701 Intellectual Property Portfolio with New U.S. Patent Covering T..
CI
2021Compugen Presents Preliminary Translational Data Demonstrating Immune Activation in the..
PR
2021Compugen Wins Fortinet Achievement Award at NSE XPERTS Summit 2021
AQ
2021Oppenheimer Adjusts Compugen PT to $17 From $19, Maintains Outperform Rating
MT
2021COMPUGEN : Q3 Earnings Snapshot
AQ
2021Compugen Narrows Net Loss in Q3, Revenue Gains on Milestone Payment
MT
2021Press Release dated November 12, 2021 – “Compugen Presents Preliminary Resu..
PU
2021Compugen Announces Collaboration Expansion with Bristol Myers Squibb alongside $20 Mill..
PU
More news
Analyst Recommendations on COMPUGEN LTD.
More recommendations
Financials (USD)
Sales 2021 6,86 M - -
Net income 2021 -37,2 M - -
Net Debt 2021 - - -
P/E ratio 2021 -8,29x
Yield 2021 -
Capitalization 316 M 316 M -
Capi. / Sales 2021 46,0x
Capi. / Sales 2022 -
Nbr of Employees 68
Free-Float 94,2%
Chart COMPUGEN LTD.
Duration : Period :
Compugen Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends COMPUGEN LTD.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Last Close Price 3,66 $
Average target price 20,57 $
Spread / Average Target 462%
EPS Revisions
Managers and Directors
Anat Cohen-Dayag President, Chief Executive Officer & Director
Ari Krashin Chief Operating & Financial Officer
Paul Jai Sekhri Chairman
Henry Adewoye Chief Medical Officer
Arie Ovadia Director
Sector and Competitors
1st jan.Capi. (M$)
COMPUGEN LTD.-11.40%328
MODERNA, INC.-34.04%67 921
LONZA GROUP AG-13.71%53 315
IQVIA HOLDINGS INC.-13.38%46 690
SEAGEN INC.-13.93%24 331
ICON PUBLIC LIMITED COMPANY-17.37%20 831